180 related articles for article (PubMed ID: 34260979)
1. Effect of one-year dextromethorphan/quinidine treatment on management of respiratory impairment in amyotrophic lateral sclerosis.
Sancho J; Ferrer S; Burés E; Luis Díaz J; Torrecilla T; Signes-Costa J; Servera E
Respir Med; 2021 Sep; 186():106536. PubMed ID: 34260979
[TBL] [Abstract][Full Text] [Related]
2. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial.
Brooks BR; Thisted RA; Appel SH; Bradley WG; Olney RK; Berg JE; Pope LE; Smith RA;
Neurology; 2004 Oct; 63(8):1364-70. PubMed ID: 15505150
[TBL] [Abstract][Full Text] [Related]
3. PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury.
Hammond FM; Alexander DN; Cutler AJ; D'Amico S; Doody RS; Sauve W; Zorowitz RD; Davis CS; Shin P; Ledon F; Yonan C; Formella AE; Siffert J
BMC Neurol; 2016 Jun; 16():89. PubMed ID: 27276999
[TBL] [Abstract][Full Text] [Related]
4. Bulbar impairment score predicts noninvasive volume-cycled ventilation failure during an acute lower respiratory tract infection in ALS.
Servera E; Sancho J; Bañuls P; Marín J
J Neurol Sci; 2015 Nov; 358(1-2):87-91. PubMed ID: 26329906
[TBL] [Abstract][Full Text] [Related]
5. Additional evidence for a therapeutic effect of dextromethorphan/quinidine on bulbar motor function in patients with amyotrophic lateral sclerosis: A quantitative speech analysis.
Green JR; Allison KM; Cordella C; Richburg BD; Pattee GL; Berry JD; Macklin EA; Pioro EP; Smith RA
Br J Clin Pharmacol; 2018 Dec; 84(12):2849-2856. PubMed ID: 30152872
[TBL] [Abstract][Full Text] [Related]
6. Dextromethorphan/quinidine for the treatment of pseudobulbar affect.
Patatanian E; Casselman J
Consult Pharm; 2014 Apr; 29(4):264-9. PubMed ID: 24704895
[TBL] [Abstract][Full Text] [Related]
7. Safety, Tolerability, and Effectiveness of Dextromethorphan/Quinidine for Pseudobulbar Affect Among Study Participants With Traumatic Brain Injury: Results From the PRISM-II Open Label Study.
Hammond FM; Sauve W; Ledon F; Davis C; Formella AE
PM R; 2018 Oct; 10(10):993-1003. PubMed ID: 29477412
[TBL] [Abstract][Full Text] [Related]
8. An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions.
Pattee GL; Wymer JP; Lomen-Hoerth C; Appel SH; Formella AE; Pope LE
Curr Med Res Opin; 2014 Nov; 30(11):2255-65. PubMed ID: 25062507
[TBL] [Abstract][Full Text] [Related]
9. Dextromethorphan/quinidine for the treatment of bulbar impairment in amyotrophic lateral sclerosis.
Tabor Gray L; Locatelli E; Vasilopoulos T; Wymer J; Plowman EK
Ann Clin Transl Neurol; 2023 Aug; 10(8):1296-1304. PubMed ID: 37265174
[TBL] [Abstract][Full Text] [Related]
10. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect.
Pioro EP; Brooks BR; Cummings J; Schiffer R; Thisted RA; Wynn D; Hepner A; Kaye R;
Ann Neurol; 2010 Nov; 68(5):693-702. PubMed ID: 20839238
[TBL] [Abstract][Full Text] [Related]
11. Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment Trial.
Smith R; Pioro E; Myers K; Sirdofsky M; Goslin K; Meekins G; Yu H; Wymer J; Cudkowicz M; Macklin EA; Schoenfeld D; Pattee G
Neurotherapeutics; 2017 Jul; 14(3):762-772. PubMed ID: 28070747
[TBL] [Abstract][Full Text] [Related]
12. Effects of dextromethorphan/quinidine on auditory event-related potentials in multiple sclerosis patients with pseudobulbar affect.
Haiman G; Pratt H; Miller A
J Clin Psychopharmacol; 2009 Oct; 29(5):444-52. PubMed ID: 19745644
[TBL] [Abstract][Full Text] [Related]
13. Do bulbar-onset amyotrophic lateral sclerosis patients have an earlier respiratory involvement than spinal-onset amyotrophic lateral sclerosis patients?
Pinto S; Pinto A; De Carvalho M
Eura Medicophys; 2007 Dec; 43(4):505-9. PubMed ID: 18084174
[TBL] [Abstract][Full Text] [Related]
14. Dextromethorphan/quinidine: in pseudobulbar affect.
Garnock-Jones KP
CNS Drugs; 2011 May; 25(5):435-45. PubMed ID: 21476614
[TBL] [Abstract][Full Text] [Related]
15. An open-label study to assess safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in dementia: PRISM II results.
Doody RS; D'Amico S; Cutler AJ; Davis CS; Shin P; Ledon F; Yonan C; Siffert J
CNS Spectr; 2016 Dec; 21(6):450-459. PubMed ID: 26471212
[TBL] [Abstract][Full Text] [Related]
16. Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis.
Panitch HS; Thisted RA; Smith RA; Wynn DR; Wymer JP; Achiron A; Vollmer TL; Mandler RN; Dietrich DW; Fletcher M; Pope LE; Berg JE; Miller A;
Ann Neurol; 2006 May; 59(5):780-7. PubMed ID: 16634036
[TBL] [Abstract][Full Text] [Related]
17. Review of Dextromethorphan 20 mg/Quinidine 10 mg (NUEDEXTA(®)) for Pseudobulbar Affect.
Pioro EP
Neurol Ther; 2014 Jun; 3(1):15-28. PubMed ID: 26000221
[TBL] [Abstract][Full Text] [Related]
18. Assessment of Use of Combined Dextromethorphan and Quinidine in Patients With Dementia or Parkinson Disease After US Food and Drug Administration Approval for Pseudobulbar Affect.
Fralick M; Sacks CA; Kesselheim AS
JAMA Intern Med; 2019 Feb; 179(2):224-230. PubMed ID: 30615021
[TBL] [Abstract][Full Text] [Related]
19. Dextromethorphan/quinidine sulfate for pseudobulbar affect.
Rosen H
Drugs Today (Barc); 2008 Sep; 44(9):661-8. PubMed ID: 19137121
[TBL] [Abstract][Full Text] [Related]
20. Predictors of need for noninvasive ventilation during respiratory tract infections in medically stable, non-ventilated subjects with amyotrophic lateral sclerosis.
Sancho J; Servera E; Bañuls P; Marin J
Respir Care; 2015 Apr; 60(4):492-7. PubMed ID: 25406348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]